These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32658968)

  • 21. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
    Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [No Abstract]   [Full Text] [Related]  

  • 22. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.
    Liu C; Bayer A; Cosgrove SE; Daum RS; Fridkin SK; Gorwitz RJ; Kaplan SL; Karchmer AW; Levine DP; Murray BE; J Rybak M; Talan DA; Chambers HF
    Clin Infect Dis; 2011 Feb; 52(3):285-92. PubMed ID: 21217178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?-No.
    Jorgensen SCJ; Spellberg B; Shorr AF; Wright WF
    Clin Infect Dis; 2021 May; 72(9):1502-1506. PubMed ID: 33740050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin in adult prescribing: is it time to move on from trough-based dosing in the UK?
    Heard F; Sehgal A
    J Antimicrob Chemother; 2021 Nov; 76(12):3071-3072. PubMed ID: 34324650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    Rybak M; Lomaestro B; Rotschafer JC; Moellering R; Craig W; Billeter M; Dalovisio JR; Levine DP
    Am J Health Syst Pharm; 2009 Jan; 66(1):82-98. PubMed ID: 19106348
    [No Abstract]   [Full Text] [Related]  

  • 27. Outcomes of a pharmacist-driven vancomycin monitoring initiative in a community hospital.
    Joseph K; Ramireddy K; Madison G; Turco T; Lui M
    J Clin Pharm Ther; 2021 Aug; 46(4):1103-1108. PubMed ID: 33768555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
    Moise-Broder PA; Forrest A; Birmingham MC; Schentag JJ
    Clin Pharmacokinet; 2004; 43(13):925-42. PubMed ID: 15509186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of pharmacist time dedicated to vancomycin dosing in adult patients using a 24-hour AUC nomogram or trough monitoring approach: A time motion study.
    Chung D; Efta J; Brunsman A; Gabriel J; Johnson J; Martz C; Stuart M; Kenney R; Smith Z
    Am J Health Syst Pharm; 2022 Jul; 79(14):1173-1179. PubMed ID: 35403665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A; Guglielmo BJ; Hersh AL
    Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R; Davis SL; Levine DP; Rybak MJ
    Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
    Liu C; Bayer A; Cosgrove SE; Daum RS; Fridkin SK; Gorwitz RJ; Kaplan SL; Karchmer AW; Levine DP; Murray BE; J Rybak M; Talan DA; Chambers HF;
    Clin Infect Dis; 2011 Feb; 52(3):e18-55. PubMed ID: 21208910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
    Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
    Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
    Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
    Pai MP; Neely M; Rodvold KA; Lodise TP
    Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
    Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
    Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N; Chavada R; Maley M; van Hal SJ
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.